Peter Bach

Peter B. Bach is a physician and writer in New York City. He is the Chief Medical Officer of DELFI Diagnostics and was previously an attending and researcher at Memorial Sloan-Kettering Cancer Center where he was the Director of the Center for Health Policy and Outcomes. His research focuses on healthcare policy, particularly as it relates to Medicare, racial disparities in cancer care quality, and lung cancer. Along with his scientific writings he is a frequent contributor to The New York Times and other newspapers.

Bach earned a bachelor's degree in English and American Literature from Harvard University (1986), a MD from the University of Minnesota (1992) and a Masters of Arts in Public Policy (1997) from the University of Chicago. He obtained his internal medicine training at Johns Hopkins Hospital, and completed a fellowship in Pulmonary and Critical Care Medicine at the University of Chicago and Johns Hopkins Hospital.[citation needed ]

In 2021 Bach joined DELFI Diagnostics, a liquid biopsy cancer screening company, as its Chief Medical Officer in 2021.

In 2012, Bach, who is a frequent critic of pharmaceutical pricing in cancer, co-authored an opinion piece in his New York Times blog outlining Memorial Sloan Kettering’s decision not to offer a new cancer drug, Zaltrap, to its patients due to the drug's price. At the time, the price for Zaltrap was more than twice as high than another cancer drug already being used by the hospital to treat colorectal cancer with similar efficacy. The New York Times piece by Bach was discussed in a 60 Minutes segment highlighting the rising cost of cancer drugs. Bach was seen as influential in the eventual lowering of Zaltrap's price by the manufacturer, Sanofi.

In 2015, Bach released DrugAbacus, billed as an interactive tool that users can apply to model prices for cancer drugs based on a number of factors, including clinical efficacy, safety and toxicity, the value placed on a year of life, and the value of innovation. The tool then allows users to compare the generated values with existing drug prices. Additionally, Bach co-authored a paper published in the American Medical Association in which he described possible value-based drug pricing approaches in the United States.[third-party source needed ]

Bach has also worked on areas related to racial disparities within the provision of cancer care. Along with research collaborators, he has published evidence that black Medicare beneficiaries with lung cancer do not receive as high quality care as white patients. A paper in 2007 demonstrated that care in Medicare is highly fragmented, with the average beneficiary seeing multiple primary care physicians and specialists.[10] He has worked on developing lung cancer screening guidelines also developed a lung cancer risk prediction model.[11][12][13][14] He has proposed a number of strategies by which Medicare could link payment level to the value of healthcare delivered.[15][16]

In 2016 Bach led an analysis that demonstrated that pharmaceutical companies were increasing revenues Notable policy

His lay press contributions have included op-eds on topics such as medical school tuition funding,[17] setting physician reimbursement based on market forces,[18] and why cancer screening recommendations are often not followed.[19]

Bach chronicled his wife Ruth’s treatment for early breast cancer in a series of articles of blog posts for the New York Times,[20] and then wrote about her death from the disease in a piece for New York Magazine.[21] Bach discussed the article on Leonard Lopate's former show on WNYC.[22]